Gastric cancer is a leading contributor to cancer incidence and mortality globally. Recently,
artificial intelligence approaches, particularly machine learning and deep learning, are …

Gastric cancer (GC) is one of the main causes of cancer incidence rate and mortality
worldwide. As the main breakthrough direction, the application of immune checkpoint …

Gastric and gastroesophageal junction (G/GEJ) cancers carry a poor prognosis, and despite
recent advancements, most patients die of their disease. Although immune checkpoint …

The synergistic effect of neoadjuvant immunotherapy and chemoradiotherapy in gastric
adenocarcinoma is unclear. This phase II trial (NCT03631615) investigated this neoadjuvant …

In this multicenter, single-arm phase 2 trial (ChiCTR1900024428), patients with locally
advanced gastric/gastroesophageal junction cancers receive one cycle of sintilimab (anti …

Perioperative chemotherapy is the standard treatment for locally advanced gastric or gastro-
esophageal junction cancer, and the addition of programmed cell death 1 (PD-1) inhibitor is …

Gastric cancer presents substantial management challenges, and the advent of
immunotherapy has ignited renewed hope among patients. Nevertheless, a significant …

Background Neoadjuvant chemotherapies have been widely recommended in patients with
locally advanced gastric cancer (LAGC). However, the evidence of combining neoadjuvant …

Gastric cancer (GC) is one of the most common malignancies. Immunotherapy becomes an
indispensable part of GC. This study conducts bibliometric analysis of immunotherapy for …

A comprehensive search regarding programmed cell death protein 1 (PD‑1)/programmed
death‑ligand 1 (PD‑L1) inhibitor monotherapy or combination therapy in neoadjuvant …